Diabetes cell-therapy firms Sernova and Seraxis announce merger

Two diabetes-focused cell-therapy companies, Sernova and Seraxis, have agreed to merge after decades of developing treatments for the disease.

The combined company aims to pool resources and expertise to advance its cell-therapy platforms, positioning itself against larger players such as Vertex and CRISPR.

Leadership of the merged entity will include incoming BetaNova CEO Jonathan Rigby and chief scientific officer William Rust.

The deal reflects a broader trend of consolidation in the cell and gene therapy sector as firms seek scale to accelerate development and commercialization.